Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function

Background: Among endocannabinoid (EC)-related mediators, Oleoyl-ethanolamide (OEA) and Palmitoylethanolamide (PEA), two endogenous PPAR alpha agonists with lipolytic and anti-inflammatory action, respectively, are being actively investigated. Here, we assessed the potential association between plasma levels of PEA and OEA and coronary function in a cohort including normal, overweight, obese, and morbidly obese (MOB) individuals.